Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126996251 | 12699625 | 1 | I | 20160823 | 20160830 | 20160830 | EXP | MX-JNJFOC-20160820289 | JANSSEN | NOLASCO-MEDINA D, REYNOSO-NOVERON N, MOHAR-BETANCOURT A, AVILES-SALAS A, GARCIA-PEREZ O, CANDELARIA M. COMPARISON OF THREE CHEMOTHERAPY REGIMENS IN ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA:EXPERIENCE AT A SINGLE NATIONAL REFERENCE CENTER IN MEXICO. BIOMED RESEARCH INTERNATIONAL 2016. | 0.00 | E | Y | 0.00000 | 20160830 | OT | MX | MX |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126996251 | 12699625 | 1 | PS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Unknown | GIVEN AT A DOSE OF 50 MG/M2 IN RCHOP GROUP AND AT A DOSE OF 25 MG/M2 IN RCHOP GROUP | U | U | 50718 | LIPOSOME INJECTION | |||||||
| 126996251 | 12699625 | 2 | SS | RITUXIMAB | RITUXIMAB | 1 | Unknown | U | 0 | 375 | MG/M**2 | UNSPECIFIED | |||||||
| 126996251 | 12699625 | 3 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Unknown | U | 0 | 750 | MG/M**2 | UNSPECIFIED | |||||||
| 126996251 | 12699625 | 4 | SS | VINCRISTINE | VINCRISTINE | 1 | Unknown | MAXIMUM DOSE 2 MG | U | 0 | 1.4 | MG/M**2 | UNSPECIFIED | ||||||
| 126996251 | 12699625 | 5 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Unknown | FOR 5 DAYS | U | 0 | 100 | MG | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126996251 | 12699625 | 1 | Diffuse large B-cell lymphoma |
| 126996251 | 12699625 | 2 | Diffuse large B-cell lymphoma |
| 126996251 | 12699625 | 3 | Diffuse large B-cell lymphoma |
| 126996251 | 12699625 | 4 | Diffuse large B-cell lymphoma |
| 126996251 | 12699625 | 5 | Diffuse large B-cell lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126996251 | 12699625 | OT |
| 126996251 | 12699625 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126996251 | 12699625 | Bone marrow failure | |
| 126996251 | 12699625 | Cardiovascular disorder | |
| 126996251 | 12699625 | Febrile neutropenia | |
| 126996251 | 12699625 | Gastrointestinal disorder | |
| 126996251 | 12699625 | Infection | |
| 126996251 | 12699625 | Lung disorder | |
| 126996251 | 12699625 | Neuropathy peripheral | |
| 126996251 | 12699625 | Off label use | |
| 126996251 | 12699625 | Pain | |
| 126996251 | 12699625 | Product use issue | |
| 126996251 | 12699625 | Renal disorder | |
| 126996251 | 12699625 | Thrombosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |